Chemotherapy remains the cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. The colorectal cancer treatment landscape has shifted toward personalized treatment, with tumor sidedness and various biomarkers playing an important role in treatment selection. The colorectal cancer market is changing, largely fueled by the entry of immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo) and BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi). Both Opdivo (with or without Yervoy) and Keytruda are approved for advanced or recurrent MSI-H / dMMR colorectal cancer. Keytruda is also approved as first-line treatment for MSI-H / dMMR metastatic colorectal cancer. Braftovi in combination with an EGFR inhibitor (Erbitux) is now available for use as subsequent therapy for metastatic colorectal cancer patients with a BRAF V600E mutation. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for colorectal cancer during the forecast period, such as the VEGFR inhibitor fruquintinib (Hutchmed) and KRAS inhibitor adagrasib (Mirati Therapeutics). These therapies will contribute to the robust market growth anticipated over the 2021-2031 forecast period.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.